Clinical Trial

Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 20, 2023 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.
Summary
The investigators will conduct a single-arm prospective study to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab (SHR-1316) and chemotherapy in patients with resectable esophageal squamous cell carcinoma (ESCC).
Trial Details
NCT Number NCT06178211
Lead Sponsor Shanghai Chest Hospital
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 36 participants
Start Date 2023-12
Primary Completion 2025-03 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2023-12-20